Abstract
The −1131C is a naturally occurring variant of the apolipoprotein A5 (ApoA5) gene, which has been shown to associate with increased triglyceride levels. This variant has also been shown to confer risk for development of ischemic heart disease and stroke. The gene is in linkage disequilibrium with factors known to correlate with impaired glucose homeostasis. These observations prompted us to study the prevalence of the ApoA5 –1131C allele in patients with metabolic syndrome. A total of 201 metabolic syndrome patients and 210 controls were studied. In both groups the triglyceride levels of patients with −1131C allele were significantly increased compared to the subjects with −1131T allele (3.22 ±0.43 mmol/1 vs. 2.24 ±0.12 mmol/1, p<0.01 in the metabolic syndrome patients; 2.10 ±0.19 mmol/1 vs. 1.22 ±0.05 mmol/1, p<0.01 in the controls). In metabolic syndrome patients the prevalence of the ApoA5 –1131C variant was increased compared to the healthy controls (11% vs. 6.20%). Multiplex regression analysis model adjusted for age, gender, serum total cholesterol levels, acute myocardial infarction and stroke events revealed that the examined ApoA5 variant confers risk for the development of metabolic syndrome: the odds ratio at 95% confidence interval was 3.622 (1.200–10.936), p=0.02. Our findings strongly suggest that this variant is a risk factor for the development of hypertriglyceridemia and metabolic syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III): JAMA 285:2486–2497, 2001
Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553, 1998
Aouizerat BE, Kulkarni M, Heilbron D, et al: Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res 44:1167–1173, 2003
Cameron AJ, Shaw JE, Zimmet PZ: The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33:351–375, 2004
Cavanaugh J: NOD2: ethnic and geographic differences. World J Gastroenterol 12:3673–3677, 2006
Connelly PW, Petrasovits A, Stachenko S, et al: Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group. Can J Cardiol 15:428–433, 1999
Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 365:1415–1428, 2005
Endo K, Yanagi H, Araki J, et al: Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 111:570–572, 2002
Evans D, Buchwald A, Beil FU: The single nucleotide polymorphism −1131T>C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia. J Mol Med 81:645–654, 2003
Genoux A, Dehondt H, Helleboid-Chapman A, et al: Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol 25:1186–1192, 2005
Groenendijk M, Cantor RM, De Bruin TW, et al: The apoAICIII–AIV gene cluster. Atherosclerosis 157:1–11, 2001
Havasi V, Szolnoki Z, Talian G, et al: Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci 29:177–183, 2006
Jakel H, Nowak M, Moitrot E, et al: The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-lc. J Biol Chem 279:45462–45469, 2004
Lai CQ, Tai ES, Tan CE, et al: The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 44:2365–2373, 2003
Martin S, Nicaud V, Humphries SE, et al: Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 1637:217–225, 2003
Merkel M, Heeren J: Give me A5 for lipoprotein hydrolysis! J Clin Invest 115:2694–2696, 2005
Merkel M, Loeffler B, Kluger M, et al: Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280:21553–21560, 2005
Nadasi E: Comparison of mtDNA haplogroups in Hungarians with four other European populations: a small incidence of descents with Asian origin. Acta Biologica Hungarica 58:245–256, 2007
Olivier M, Wang X, Cole R, et al: Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 83:912–923, 2004
Pennacchio LA, Olivier M, Hubacek JA, et al: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294:169–173, 2001
Pennacchio LA, Olivier M, Hubacek JA, et al: Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11:3031–3038, 2002
Pennacchio LA, Rubin EM: Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol 23:529–534, 2003
Permutt MA, Wasson J, Cox N: Genetic epidemiology of diabetes. J Clin Invest 115:1431–1439, 2005
Prieur X, Coste H, Rodriguez JC: The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptoralpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem 278:25468–25480, 2003
Reaven G: The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 33:283–303, 2004
Reaven P: Metabolic syndrome. J Insur Med 36:132–142, 2004
Salas J, Jansen S, Lopez-Miranda J, et al: The SstI polymorphism of the apolipoprotein C-III gene determines the insulin response to an oral-glucose-tolerance test after consumption of a diet rich in saturated fats. Am J Clin Nutr 68:396–401, 1998
Semino O, Passarino G, Quintana-Murci L, et al: MtDNA and Y chromosome polymorphisms in Hungary: inferences from the palaeolithic, neolithic and Uralic influences on the modern Hungarian gene pool. Eur J Hum Genet 8:339–346, 2000
Szalai C, Keszei M, Duba J, et al: Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Athero-sclerosis 173:109–114, 2004
Talmud PJ, Howe E, Martin S, et al: Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11:3039–3046, 2002
Waterworth DM, Hubacek JA, Pitha J, et al: Plasma levels of remnant particles are determined in part by variation in the APOC3 gene insulin response element and the APOCI-APOE cluster. J Lipid Res 41:1103–1109, 2000
Wright WT, Young IS, Nicholls DP, et al: SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population. Atherosclerosis 185:353–360, 2006
Yamada Y, Kato K, Hibino T, et al: Prediction of genetic risk for metabolic syndrome. Atherosclerosis 191:298–304, 2006
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maász, A., Kisfali, P., Horvatovich, K. et al. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol. Oncol. Res. 13, 243–247 (2007). https://doi.org/10.1007/BF02893505
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893505